Insight on AI – July 2026, Issue 15
Welcome to the July, Issue 15 edition of Artificial Vigilance, Essjay Solutions, Insight on AI, dedicated to helping pharmacovigilance professionals understand, engage with and adapt to the rapidly evolving world of artificial intelligence.
Innovation
AI-Designed Proteins Could Make Cancer Medicines Smarter
Researchers at the Dana-Farber Cancer Institute have developed an AI system capable of designing custom proteins that bind to specific drug molecules, opening new possibilities for safer, more targeted cancer treatments. The Neural Iterative Selection Expansion (NISE) platform rapidly designs proteins predicted to bind therapeutic compounds before laboratory validation begins.
The technology has successfully generated proteins capable of stabilising chemotherapy drugs and has also been used to design proteins that bind the blood thinner apixaban, demonstrating potential future applications in drug antidotes, targeted delivery and toxicity reduction.
Although still at an early research stage, AI-driven protein engineering could significantly reduce development timelines and support the next generation of precision medicines.
Industry News
Pharmacovigilance Automation Market Set to Double by 2035
AI is becoming a major driver of pharmacovigilance transformation, with a new market report predicting the global PV automation market will almost double from $2.8 billion in 2025 to $5.25 billion by 2035. Growing adverse event volumes, increasingly complex regulatory requirements and pressure to improve efficiency are accelerating investment in AI-powered drug safety platforms.
Natural language processing, cloud-based safety platforms and automated adverse event reporting are allowing organisations to extract safety data from literature and electronic health records while streamlining global regulatory reporting. More than 90% of large pharmaceutical companies are now estimated to use digital adverse event reporting systems connected to automated safety databases.
While human oversight remains essential, automation is rapidly becoming a competitive necessity as pharmacovigilance continues its transition towards AI-assisted drug safety operations.
Regulation News
The Ethics of AI Regulation in Neurology
AI is transforming neurological research by helping identify drug targets, interpret brain scans and predict patient outcomes. However, researchers argue that the greatest challenge is not technological advancement but ensuring ethical governance keeps pace with increasingly powerful AI systems.
Concerns include protecting sensitive neural data, preventing algorithmic bias caused by underrepresented patient populations and improving transparency in deep learning systems. In neurology, where AI-driven decisions can significantly influence diagnosis and treatment, explainability remains critical for maintaining clinician and patient trust.
Experts believe AI can transform neurological medicine only if privacy, fairness, transparency and appropriate regulation evolve alongside the technology.
